Literature DB >> 31264293

Long-term complications and reconstruction failures in previously radiated breast cancer patients receiving salvage mastectomy with autologous reconstruction or tissue expander/implant-based reconstruction.

Bindu V Manyam1, Chirag Shah1, Neil M Woody1, Chandana A Reddy1, Michael A Weller1, Aditya Juloori1, Mihir Naik1, Stephanie Valente2, Stephen Grobmyer2, Paul Durand3, Risal Djohan3, Rahul D Tendulkar1.   

Abstract

Salvage mastectomy (SM) is the standard of care for patients with local recurrence (LR) after breast conservation therapy (BCT), often with immediate reconstruction. Complications of reconstruction are a concern for these patients, and long-term data are limited. We sought to compare rates of complications requiring re-operation (CRR) and reconstruction failure (RF) between autologous reconstruction (AR) and tissue expander/implant reconstruction (TE/I). Patients with locally recurrent breast cancer after BCT, treated with SM and immediate AR or TE/I between 2000 and 2008, were identified. CRR was defined as unplanned return to operating room for wound infection, dehiscence, necrosis (including flap, skin, or fat), hematoma, or hernia (for AR) and extrusion, leak, or capsular contracture (for TE/I). RF was defined as conversion to another reconstruction technique or to flat chest wall. This study included 103 patients with 107 reconstructions. Median follow-up was 6.6 years. CRR and RF were significantly higher with TE/I (n = 34) compared to AR (n = 73) at 5 years (50.9% vs 25.5%; P = 0.02) and (42.1% vs 5.8%; P < 0.001). On univariate analysis (UVA), TE/I (HR = 2.14; P = 0.02) and diabetes (HR = 5.10; P = 0.007) were significant predictors for CRR. On UVA, TE/I (HR = 7.30; P < 0.001) and older age at reconstruction (HR = 1.03; P = 0.003) were significant predictors for RF. In this population of previously irradiated patients, TE/I was associated with significantly higher CRR and RF. Complications continue to occur up to 10 years after TE/I. AR should be considered in appropriately selected patients, though TE/I may remain a reasonable option in patients without high-risk factors for surgical complications.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  autologous; breast cancer; expander; reconstruction; toxicity

Mesh:

Year:  2019        PMID: 31264293     DOI: 10.1111/tbj.13428

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  6 in total

1.  The effect of radiotherapy on fat engraftment for complete breast reconstruction using lipofilling only.

Authors:  Norbert Heine; Andreas Eigenberger; Vanessa Brebant; Sally Kempa; Stephan Seitz; Lukas Prantl; Britta Kuehlmann
Journal:  Arch Gynecol Obstet       Date:  2022-05-30       Impact factor: 2.344

Review 2.  Implant-Based Breast Reconstruction after Mastectomy, from the Subpectoral to the Prepectoral Approach: An Evidence-Based Change of Mind?

Authors:  Andrea Weinzierl; Daniel Schmauss; Davide Brucato; Yves Harder
Journal:  J Clin Med       Date:  2022-05-30       Impact factor: 4.964

3.  Failed Breast Conservation Therapy Predicts Higher Frequency of Revision Surgery following Mastectomy with Reconstruction.

Authors:  Danielle H Rochlin; Clifford C Sheckter; Arash Momeni
Journal:  Plast Reconstr Surg       Date:  2022-04-01       Impact factor: 5.169

4.  Implant-based versus Autologous Reconstruction after Mastectomy for Breast Cancer: A Systematic Review and Meta-analysis.

Authors:  Justin M Broyles; Ethan M Balk; Gaelen P Adam; Wangnan Cao; Monika Reddy Bhuma; Shivani Mehta; Laura S Dominici; Andrea L Pusic; Ian J Saldanha
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-03-11

Review 5.  3D and 4D Printing in the Fight against Breast Cancer.

Authors:  Sofia Moroni; Luca Casettari; Dimitrios A Lamprou
Journal:  Biosensors (Basel)       Date:  2022-07-26

Review 6.  3D Printing in Breast Reconstruction: From Bench to Bed.

Authors:  Xingdou Mu; Juliang Zhang; Yue Jiang
Journal:  Front Surg       Date:  2021-05-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.